Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis

PRESS RELEASE FDA Approval

13/10/2021

AstraZeneca

Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE).

Related News

Tezepelumab is the first biologic to consistently and significantly reduce exacerbations in broad population of severe asthma patients

To discover more on this topic, please tap 'Read more'.

04/03/2021

PRESS RELEASE Product Launch

New tezepelumab data continue to strengthen profile for a broad population of severe asthma patients

To discover more on this topic, please tap 'Read more'.

20/05/2021

PRESS RELEASE Research Findings

New DUPIXENT® (dupilumab) data showcasing improvements across four type 2 inflammatory diseases to be presented at 2021 AAAAI annual meeting

To discover more on this topic, please tap 'Read more'.

02/02/2021

PRESS RELEASE Research Findings

ASEC Frontier (Thailand) Co., Ltd

Address : 1 Empire Tower, Unit 1509 15th floor South Sathorn road Yannawa Sathorn Bangkok, Thailand 10120

Tel : +662-118-0873

Email : info@medical-leaders-thailand.com

Website : www.asec-frontier.com

 

Contact Us